X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
oncology (17) 17
male (12) 12
chemotherapy (10) 10
middle aged (9) 9
index medicus (8) 8
adult (7) 7
female (7) 7
treatment outcome (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
breast cancer (6) 6
prostatic neoplasms - drug therapy (6) 6
aged (5) 5
breast neoplasms - drug therapy (5) 5
cancer (5) 5
neoplasm staging (5) 5
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cisplatin (4) 4
doxorubicin (4) 4
follow-up (4) 4
prostate cancer (4) 4
urology & nephrology (4) 4
administration, oral (3) 3
aged, 80 and over (3) 3
androgen antagonists - therapeutic use (3) 3
breast neoplasms - metabolism (3) 3
breast neoplasms - pathology (3) 3
carcinoma (3) 3
chemotherapy, adjuvant (3) 3
combined modality therapy (3) 3
disease-free survival (3) 3
drug therapy (3) 3
genes (3) 3
gonadotropin-releasing hormone - antagonists & inhibitors (3) 3
metastasis (3) 3
methotrexate (3) 3
orchiectomy (3) 3
paclitaxel (3) 3
prognosis (3) 3
prostate-specific antigen - blood (3) 3
prostatic neoplasms - surgery (3) 3
quality of life (3) 3
research (3) 3
therapy (3) 3
time factors (3) 3
trastuzumab (3) 3
vinblastine (3) 3
adenocarcinoma - drug therapy (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols (2) 2
breast neoplasms - genetics (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, transitional cell - drug therapy (2) 2
carcinoma, transitional cell - secondary (2) 2
care and treatment (2) 2
clinical trials (2) 2
deoxycytidine - analogs & derivatives (2) 2
diethylstilbestrol (2) 2
diethylstilbestrol - therapeutic use (2) 2
disease progression (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
erbb-2 protein (2) 2
expression (2) 2
feasibility studies (2) 2
follow-up studies (2) 2
genetic aspects (2) 2
gonadotropin-releasing hormone - agonists (2) 2
health aspects (2) 2
hematology, oncology and palliative medicine (2) 2
kaplan-meier estimate (2) 2
metastatic carcinoma (2) 2
neoadjuvant (2) 2
neoadjuvant therapy (2) 2
neoplasm invasiveness (2) 2
neoplasms, hormone-dependent - drug therapy (2) 2
open-label (2) 2
phase-ii trial (2) 2
phase-iii trials (2) 2
prednisone (2) 2
proportional hazards models (2) 2
prostatic neoplasms - physiopathology (2) 2
prostatic neoplasms - radiotherapy (2) 2
radiation-therapy (2) 2
radical prostatectomy (2) 2
receptor, erbb-2 - metabolism (2) 2
receptors, estrogen - metabolism (2) 2
risk assessment (2) 2
risk factors (2) 2
sensitivity (2) 2
survival (2) 2
survival rate (2) 2
testicular neoplasms - therapy (2) 2
urology (2) 2
5-fluorouracil (1) 1
abridged index medicus (1) 1
abstracts (1) 1
acetate (1) 1
acquired-resistance (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 03/2019, Volume 20, Issue 2, pp. 74 - 81.e1
Cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was... 
RET | KRAS | AXL | Disease control | MET | TARGETED THERAPY | ACQUIRED-RESISTANCE | OPEN-LABEL | CANCER | EGFR | ONCOLOGY | CRIZOTINIB | INHIBITORS | MUTATIONS
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 2013, Volume 11, Issue 2, pp. 175 - 181
Micro-Abstract Parallel trials in advanced disease and neoadjuvant settings are attractive for accelerating drug development in bladder cancer. However, the... 
Hematology, Oncology and Palliative Medicine | Urology | Neoadjuvant | Chemotherapy | Hematologic toxicity | Phase II | Antiangiogenic therapy | COLONY-STIMULATING FACTOR | DOXORUBICIN | METHOTREXATE | RANDOMIZED-TRIAL | VINBLASTINE | FIBROBLAST-GROWTH-FACTOR | PHASE-III TRIAL | TRANSITIONAL-CELL-CARCINOMA | ONCOLOGY | UROLOGY & NEPHROLOGY | INHIBITOR TNP-470 AGM-1470 | COOPERATIVE-ONCOLOGY-GROUP | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Male | Antineoplastic Agents - therapeutic use | Urothelium - pathology | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Neoadjuvant Therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Urinary Bladder Neoplasms - mortality | Neoplasm Invasiveness | Survival Rate | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Antimetabolites, Antineoplastic - therapeutic use | Indoles - adverse effects | Carcinoma, Transitional Cell - pathology | Cisplatin - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Carcinoma, Transitional Cell - drug therapy | Cisplatin - adverse effects | Indoles - therapeutic use | Aged | Carcinoma, Transitional Cell - surgery | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5_suppl, pp. 285 - 285
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5_suppl, pp. 282 - 282
Journal Article
Community Oncology, ISSN 1548-5315, 11/2007, Volume 4, Issue 11, pp. 2 - 8
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 05/2002, Volume 14, Issue 3, pp. 260 - 264
Testicular cancer remains a major success story in the realm of solid tumors. Although testicular cancer is highly treatable and curable, there are still many... 
CISPLATIN | ONCOLOGY | DISEASE | CYCLES | GERM-CELL TUMORS | RISK | STAGE-I | RADIOTHERAPY | SEMINOMA | EXPRESSION | CHEMOTHERAPY | Testicular Neoplasms - diagnosis | Testicular Neoplasms - therapy | Testicular Neoplasms - genetics | Humans | Risk Factors | Quality of Life | Male | Antineoplastic Agents - therapeutic use | Biomarkers, Tumor
Journal Article